Dr. High is a hematologist and a pioneer in the field of gene therapy. She has been instrumental in establishing proof of concept for gene therapy, and has pioneered safe and effective clinical translation of genetic therapies for inherited disorders. Previously, Dr. High was an investigator for the Howard Hughes Medical Institute. She also held an endowed chair at the University of Pennsylvania’s Perelman School of Medicine. Dr. High currently serves as the President & Chief Scientific Officer of Spark Therapeutics, where she spearheads gene therapy research in a number of disease areas. She is past president of the American Society of Gene and Cell Therapy, and served a five-year term on the FDA Advisory Committee on Cell, Gene and Tissue Therapies.
J. Fraser Wright, Ph.D.
For more than 20 years, J. Fraser Wright has been a leader in the field of viral, vector-based technology and translational research. As an innovator in gene therapy vector design and development, Dr. Wright established and directed the Clinical Vector Core lab at Children’s Hospital of Philadelphia (CHOP), before becoming Spark’s scientific co-founder and Chief Technology Officer. While at CHOP, Dr. Wright led his team to the successful use of adeno-associated viral vectors as a delivery mechanism in gene therapy clinical trials.
Daniel C. Chung, D.O.
Dr. Chung, a former senior investigator at the FM Kirby Center for Molecular Ophthalmology at the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine, has spent more than 15 years advancing the science of viral and non-viral gene transfer/gene therapy for the potential treatment of inherited retinal diseases. Dr. Chung trained as a pediatric ophthalmologist, with additional training in inherited retinal disease and gene therapy. He has been instrumental in RPE65 gene therapy clinical trials at The Children’s Hospital of Philadelphia. Dr. Chung now serves as the Clinical Ophthalmic Lead at Spark Therapeutics.